
Senores (SENORES) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
1.1B
Gross Profit
567.6M
49.70%
Operating Income
142.1M
12.44%
Net Income
179.7M
15.73%
Balance Sheet Metrics
Total Assets
12.3B
Total Liabilities
4.1B
Shareholders Equity
8.1B
Debt to Equity
0.51
Cash Flow Metrics
Revenue & Profitability Trend
Senores Income Statement From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue | 4.0B | 2.1B | 353.3M | 140.7M |
Cost of Goods Sold | 1.8B | 1.1B | 127.7M | 80.3M |
Gross Profit | 2.2B | 1.1B | 225.6M | 60.3M |
Gross Margin % | 54.6% | 50.5% | 63.9% | 42.9% |
Operating Expenses | ||||
Research & Development | - | 40.0K | 0 | 0 |
Selling, General & Administrative | - | 140.2M | 14.9M | 9.7M |
Other Operating Expenses | 674.8M | 313.5M | 34.7M | 3.4M |
Total Operating Expenses | 674.8M | 453.7M | 49.6M | 13.1M |
Operating Income | 728.6M | 315.5M | 108.9M | 12.5M |
Operating Margin % | 18.3% | 14.7% | 30.8% | 8.9% |
Non-Operating Items | ||||
Interest Income | - | 4.6M | 390.0K | 1.9M |
Interest Expense | 215.5M | 94.5M | 18.4M | 5.1M |
Other Non-Operating Income | - | - | - | - |
Pre-tax Income | 705.7M | 249.4M | 124.4M | 11.4M |
Income Tax | 122.3M | -77.6M | 40.0M | 1.5M |
Effective Tax Rate % | 17.3% | -31.1% | 32.2% | 13.3% |
Net Income | 583.4M | 327.1M | 84.3M | 9.9M |
Net Margin % | 14.6% | 15.2% | 23.9% | 7.0% |
Key Metrics | ||||
EBITDA | 1.1B | 444.1M | 160.6M | 23.6M |
EPS (Basic) | ₹16.12 | ₹6.83 | ₹1.83 | ₹0.22 |
EPS (Diluted) | ₹16.12 | ₹6.83 | ₹1.83 | ₹0.22 |
Basic Shares Outstanding | 36327543 | 46053588 | 46053588 | 46053588 |
Diluted Shares Outstanding | 36327543 | 46053588 | 46053588 | 46053588 |
Income Statement Trend
Senores Balance Sheet From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Assets | ||||
Current Assets | ||||
Cash & Equivalents | 1.1B | 76.5M | 1.0M | 20.2M |
Short-term Investments | 4.0B | 52.1M | - | 12.0M |
Accounts Receivable | 1.2B | 1.1B | 221.1M | 196.3M |
Inventory | 566.3M | 373.7M | 31.2M | 29.8M |
Other Current Assets | 394.5M | - | - | - |
Total Current Assets | 7.2B | 2.5B | 513.4M | 270.5M |
Non-Current Assets | ||||
Property, Plant & Equipment | 2.1B | 2.0M | 1.7M | 0 |
Goodwill | 2.6B | 1.9B | 464.4M | 88.4M |
Intangible Assets | 1.8B | 1.2B | 464.4M | 88.4M |
Long-term Investments | - | - | - | - |
Other Non-Current Assets | 73.8M | - | 10.0K | 20.0K |
Total Non-Current Assets | 5.0B | 3.7B | 797.2M | 321.0M |
Total Assets | 12.3B | 6.2B | 1.3B | 591.5M |
Liabilities | ||||
Current Liabilities | ||||
Accounts Payable | 672.2M | 1.1B | 135.8M | 71.4M |
Short-term Debt | 1.4B | 1.2B | 312.8M | 21.3M |
Current Portion of Long-term Debt | - | - | - | - |
Other Current Liabilities | 60.3M | - | - | - |
Total Current Liabilities | 2.4B | 2.5B | 518.8M | 98.8M |
Non-Current Liabilities | ||||
Long-term Debt | 1.7B | 1.4B | 313.2M | 126.2M |
Deferred Tax Liabilities | 0 | 0 | 21.0M | 0 |
Other Non-Current Liabilities | -100.0K | - | - | - |
Total Non-Current Liabilities | 1.7B | 1.4B | 336.7M | 126.8M |
Total Liabilities | 4.1B | 3.9B | 855.5M | 225.6M |
Equity | ||||
Common Stock | 460.5M | 305.0M | 98.2M | 87.4M |
Retained Earnings | - | 415.7M | 101.1M | 16.8M |
Treasury Stock | - | - | - | - |
Other Equity | - | - | - | - |
Total Shareholders Equity | 8.1B | 2.3B | 455.0M | 365.9M |
Key Metrics | ||||
Total Debt | 3.1B | 2.6B | 625.9M | 147.6M |
Working Capital | 4.8B | 34.1M | -5.5M | 171.7M |
Balance Sheet Composition
Senores Cash Flow Statement From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Operating Activities | ||||
Net Income | 705.7M | 249.4M | 124.4M | 11.4M |
Depreciation & Amortization | - | - | - | - |
Stock-Based Compensation | - | - | - | - |
Working Capital Changes | -909.5M | -1.2B | -228.0M | -196.3M |
Operating Cash Flow | -71.8M | -846.1M | -85.6M | -181.7M |
Investing Activities | ||||
Capital Expenditures | -1.6B | -518.3M | -472.8M | -106.8M |
Acquisitions | -36.9M | -32.9M | -10.5M | -139.5M |
Investment Purchases | - | - | - | - |
Investment Sales | - | - | - | - |
Investing Cash Flow | -1.6B | -551.1M | -483.3M | -246.3M |
Financing Activities | ||||
Share Repurchases | - | - | - | - |
Dividends Paid | - | - | - | - |
Debt Issuance | - | - | - | - |
Debt Repayment | - | - | - | - |
Financing Cash Flow | 5.6B | 936.8M | 305.4M | 280.7M |
Free Cash Flow | -2.0B | -775.3M | -483.6M | -211.3M |
Net Change in Cash | 4.0B | -460.4M | -263.5M | -147.3M |
Cash Flow Trend
Senores Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
44.41
Forward P/E
17.63
Price to Book
3.88
Price to Sales
6.59
PEG Ratio
0.33
Profitability Ratios
Profit Margin
14.82%
Operating Margin
20.42%
Return on Equity
7.21%
Return on Assets
4.77%
Financial Health
Current Ratio
3.00
Debt to Equity
38.75
Per Share Data
EPS (TTM)
₹14.69
Book Value per Share
₹168.00
Revenue per Share
₹116.47
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
senores | 30.0B | 44.41 | 3.88 | 7.21% | 14.82% | 38.75 |
GlaxoSmithKline | 453.6B | 47.75 | 23.25 | 47.54% | 25.41% | 0.51 |
Pfizer | 229.7B | 29.76 | 5.42 | 19.65% | 33.65% | 2.57 |
Sms Pharmaceuticals | 19.9B | 27.49 | 3.11 | 11.76% | 8.83% | 48.58 |
TTK Healthcare | 16.1B | 25.58 | 1.51 | 7.67% | 7.69% | 2.27 |
Kopran | 7.7B | 21.93 | 1.47 | 7.44% | 5.58% | 28.51 |
Financial data is updated regularly. All figures are in the company's reporting currency.